CSP EXAM TEST
PDCbmcalculationbm-bmanswers--PDCbm=bm(#bmofbmuniquebmdaysbmwithbmsupplybm/
bmnumberbmofbmdaysbminbmabmperiod)bmxbm100
WhichbmmedicationbmisbmabmJakbminhibitor?
a.bmHumirabm(adalimumab)
b.bmOrenciabm(abatacept)
c.bmActemrabm(toclizumab)
d.bmXeljanzbm(tofacitinib)bm-bmanswers--d.bmXeljanzbm(tofacitinib)
Whichbmmedicationbmcanbmelevatebmcholesterol?
a.bmActemrabm(toclizumab)
b.bmEnbrelbm(etanercept)
c.bmSimponibm(golimumab)
d.bmKineretbm(anakinra)bm-bmanswers--a.bmActemrabm(toclizumab)
WhichbmshinglesbmvaccinebmisbmsafebmtobmadministerbmwithbmTNFbminhibitors?
a.bmAdacel
b.bmZostavax
c.bmShingrix
d.bmVarivaxbm-bmanswers--c.bmShingrix
Mostbmbiologicsbmincreasebmthebmriskbmofbminfections,bmwhichbmofbmthebmfollowingbmalsobmincreasesb
mthebmriskbmof
neutropenia?
a.bmRituxinbm(rituximab)
,b.bmTaltzbm(ixekizumab)
c.bmRemicadebm(infliximab)
d.bmCimziabm(certolizumabbmpegol)bm-bmanswers--b.bmTaltzbm(ixekizumab)
Whichbmpsoriasisbmmedicationbmdoesbmnotbmrequirebmscreeningbmforbmtuberculosis?
a.bmStelarabm(ustekinumab)
b.bmOtezlabm(apremilast)
c.bmCocentyxbm(seculinumab)
d.bmHumirabm(adalimumab)bm-bmanswers--b.bmOtezlabm(apremilast)
WhatbmisbmthebmstandardbmstartingbmdosebmforbmTaltzbm(ixekizumab)bmwhenbmusedbmtobmtreatbmpsori
aticbmarthritis?
a.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmatbmweeksbm2,bm4,bm6,
bm8,bm10
andbm12;bmthenbm80mgbmsubcutaneouslybmeverybm4bmweeks
b.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybm4bmweeks
c.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybmweekbmforbm4b
mweeks,
thenbm80mgbmeverybm4bmweeks
d.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybmotherbmweekbm
-bmanswers--
b.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybm4bmweeks
Abm45bmy/
o,bm200lbbmpatientbmisbmstrugglingbmwithbmseverebmdermatitisbmandbmthebmproviderbmwantsbmtobmpo
tentially
startbmabmbiologic.bmWhichbmmedicationbmwouldbmyoubmrecommend?
a.bmProtopicbm(tacrolimus)
b.bmHumirabm(adalimumab)
c.bmStelarabm(ustekinumab)
d.bmDupixentbm(dupilumab)bm-bmanswers--d.bmDupixentbm(dupilumab)
, Abm56bmy/
o,bm140lbbmpatientbmwithbmpsoriasisbmwillbmbebmstartingbmStelarabm(ustekinumab),bmbutbmthebmprovi
der
wantsbmtobmverifybmthebmdosingbmofbmthebmmedication.bmWhatbmstartingbmdosebmwouldbmyoubmreco
mmend?
a.bmInjectbm45bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm45bmmgbmeverybm12
bmweeks
b.bmInjectbm90bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm90bmmgbmeverybm12
bmweeks
c.bmInfusebm260bmmgbmIVbmoverbmatbmleastbm1bmhourbmasbmabmsinglebmdose,bmfollowedbm8bmweeksb
mlaterbmwithbm90bmmg
subcutaneouslybmeverybm8bmweeks
d.bmInfusebm520bmmgbmIVbmoverbmatbmleastbm1bmhourbmasbmabmsinglebmdose,bmfollowedbm8bmweeksb
mlaterbmwithbm90bmmg
subcutaneouslybmeverybm8bmweeksbm-bmanswers--
a.bmInjectbm45bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm45bmmgbmeverybm12
bmweeks
WhichbmofbmthebmfollowingbmoralbmoncologybmmedicationsbmdoesbmNOTbmrequirebmusingbmcautionbmi
nbmpatients
withbmhepaticbmimpairment?
a.bmVotrientbm(pazopanib)
b.bmIbrancebm(palbociclib)
c.bmZytigabm(abirateronebmacetate)
d.bmTykerbbm(lapatinib)bm-bmanswers--b.bmIbrancebm(palbociclib)
WhichbmsidebmeffectbmlistedbmbelowbmisbmNOTbmabmsidebmeffectbmofbmZytigabm(abirateronebmacetate)
?
a.bmEdema
b.bmHotbmflush
c.bmHepatotoxicity
d.bmMucositisbm-bmanswers--d.bmMucositis
PDCbmcalculationbm-bmanswers--PDCbm=bm(#bmofbmuniquebmdaysbmwithbmsupplybm/
bmnumberbmofbmdaysbminbmabmperiod)bmxbm100
WhichbmmedicationbmisbmabmJakbminhibitor?
a.bmHumirabm(adalimumab)
b.bmOrenciabm(abatacept)
c.bmActemrabm(toclizumab)
d.bmXeljanzbm(tofacitinib)bm-bmanswers--d.bmXeljanzbm(tofacitinib)
Whichbmmedicationbmcanbmelevatebmcholesterol?
a.bmActemrabm(toclizumab)
b.bmEnbrelbm(etanercept)
c.bmSimponibm(golimumab)
d.bmKineretbm(anakinra)bm-bmanswers--a.bmActemrabm(toclizumab)
WhichbmshinglesbmvaccinebmisbmsafebmtobmadministerbmwithbmTNFbminhibitors?
a.bmAdacel
b.bmZostavax
c.bmShingrix
d.bmVarivaxbm-bmanswers--c.bmShingrix
Mostbmbiologicsbmincreasebmthebmriskbmofbminfections,bmwhichbmofbmthebmfollowingbmalsobmincreasesb
mthebmriskbmof
neutropenia?
a.bmRituxinbm(rituximab)
,b.bmTaltzbm(ixekizumab)
c.bmRemicadebm(infliximab)
d.bmCimziabm(certolizumabbmpegol)bm-bmanswers--b.bmTaltzbm(ixekizumab)
Whichbmpsoriasisbmmedicationbmdoesbmnotbmrequirebmscreeningbmforbmtuberculosis?
a.bmStelarabm(ustekinumab)
b.bmOtezlabm(apremilast)
c.bmCocentyxbm(seculinumab)
d.bmHumirabm(adalimumab)bm-bmanswers--b.bmOtezlabm(apremilast)
WhatbmisbmthebmstandardbmstartingbmdosebmforbmTaltzbm(ixekizumab)bmwhenbmusedbmtobmtreatbmpsori
aticbmarthritis?
a.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmatbmweeksbm2,bm4,bm6,
bm8,bm10
andbm12;bmthenbm80mgbmsubcutaneouslybmeverybm4bmweeks
b.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybm4bmweeks
c.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybmweekbmforbm4b
mweeks,
thenbm80mgbmeverybm4bmweeks
d.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybmotherbmweekbm
-bmanswers--
b.bm160mgbmsubcutaneouslybmonce,bmfollowedbmbybm80mgbmsubcutaneouslybmeverybm4bmweeks
Abm45bmy/
o,bm200lbbmpatientbmisbmstrugglingbmwithbmseverebmdermatitisbmandbmthebmproviderbmwantsbmtobmpo
tentially
startbmabmbiologic.bmWhichbmmedicationbmwouldbmyoubmrecommend?
a.bmProtopicbm(tacrolimus)
b.bmHumirabm(adalimumab)
c.bmStelarabm(ustekinumab)
d.bmDupixentbm(dupilumab)bm-bmanswers--d.bmDupixentbm(dupilumab)
, Abm56bmy/
o,bm140lbbmpatientbmwithbmpsoriasisbmwillbmbebmstartingbmStelarabm(ustekinumab),bmbutbmthebmprovi
der
wantsbmtobmverifybmthebmdosingbmofbmthebmmedication.bmWhatbmstartingbmdosebmwouldbmyoubmreco
mmend?
a.bmInjectbm45bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm45bmmgbmeverybm12
bmweeks
b.bmInjectbm90bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm90bmmgbmeverybm12
bmweeks
c.bmInfusebm260bmmgbmIVbmoverbmatbmleastbm1bmhourbmasbmabmsinglebmdose,bmfollowedbm8bmweeksb
mlaterbmwithbm90bmmg
subcutaneouslybmeverybm8bmweeks
d.bmInfusebm520bmmgbmIVbmoverbmatbmleastbm1bmhourbmasbmabmsinglebmdose,bmfollowedbm8bmweeksb
mlaterbmwithbm90bmmg
subcutaneouslybmeverybm8bmweeksbm-bmanswers--
a.bmInjectbm45bmmgbmsubcutaneouslybmatbmweeksbm0bmandbm4,bmfollowedbmbybm45bmmgbmeverybm12
bmweeks
WhichbmofbmthebmfollowingbmoralbmoncologybmmedicationsbmdoesbmNOTbmrequirebmusingbmcautionbmi
nbmpatients
withbmhepaticbmimpairment?
a.bmVotrientbm(pazopanib)
b.bmIbrancebm(palbociclib)
c.bmZytigabm(abirateronebmacetate)
d.bmTykerbbm(lapatinib)bm-bmanswers--b.bmIbrancebm(palbociclib)
WhichbmsidebmeffectbmlistedbmbelowbmisbmNOTbmabmsidebmeffectbmofbmZytigabm(abirateronebmacetate)
?
a.bmEdema
b.bmHotbmflush
c.bmHepatotoxicity
d.bmMucositisbm-bmanswers--d.bmMucositis